As inhalation therapies expand beyond traditional respiratory applications, developers are exploring new opportunities in RNA therapeutics, biologics, vaccines, oncology, and CNS-targeted treatments. However, inhalation drug development presents unique challenges; from formulation design and particle engineering to device compatibility, analytical testing, and scalable manufacturing.
In this article, published in the June 2026 issue of Contract Pharma magazine, Justin Lacombe, Ph.D., Chief Scientific Officer at Experic, and Brian Fagan, Vice President, Technical Sales, examine the scientific and operational complexities behind inhalation drug development and discuss the expertise required to successfully bring these advanced therapies from concept to clinic.